Literature DB >> 24988054

Excellent Cancer Outcomes Following Patient-adapted Robotic Lung SBRT But a Case for Caution in Idiopathic Pulmonary Fibrosis.

Houda Bahig1, Edith Filion1, Toni Vu1, David Roberge1, Louise Lambert1, Myriam Bouchard2, Caroline Lavoie3, Robert Doucet1, Dominic Béliveau Nadeau1, Jean Chalaoui1, Marie-Pierre Campeau4.   

Abstract

The aim of this study is to report outcomes and prognostic factors for early stage non-small cell lung cancer treated with patient-adapted Cyberknife stereotactic body radiotherapy. A retrospective analysis of 150 patients with T1-2N0 non-small cell lung cancer treated with stereotactic body radiotherapy was conducted. An algorithm based on tumor and patient's characteristics was used to orient patients towards soft tissue (Xsight Lung), fiducials or adjacent bone (Xsight Spine) tracking. Median biological effective dose without correction for tissue inhomogeneities was 180 Gy10 for peripheral tumors and 113 Gy10 for central tumors. Median follow-up was 22 months. Actuarial 2 years local control, overall survival and disease-specific survival were respectively 96%, 87% and 95%. Every 1 cm increase in tumor diameter was associated with a relative risk for regional or distant relapse of 2 (95%CI = 1.2-3.6, p = 0.009). With doses ≥132 Gy10 and <132 Gy10, local control was 98% vs. 82% (p = 0.07), disease-specific survival 97% vs. 78% (p = 0.02) and overall survival 93% vs. 76% (p = 0.01), respectively. Better disease-specific survival and a trend for better overall survival was observed for peripheral vs. central tumors (96% vs. 79%, p = 0.05 and 92% vs. 74%, p = 0.08, respectively). A higher Charlson comordibity score (≥4) predicted lower overall survival (79% vs. 98%, p = 0.01). Toxicities included 3 patients with idiopathic pulmonary fibrosis who developed grade 5 pneumonitis and 2 patients with grade 3 pneumonitis. We therefore report excellent local control and disease-specific survival following patient-adapted Cyberknife lung stereotactic body radiotherapy. Although toxicities were in general minimal, patients with pulmonary fibrosis might be at greater risk of severe complications. Small size, peripheral location, dose ≥ 132 Gy10 and a low Charlson co-morbidity score seem to be associated with better outcomes.
© The Author(s) 2014.

Entities:  

Keywords:  Cyberknife; Lung SBRT; Prognostic factors; Pulmonary fibrosis

Mesh:

Year:  2014        PMID: 24988054     DOI: 10.7785/tcrt.2012.500445

Source DB:  PubMed          Journal:  Technol Cancer Res Treat        ISSN: 1533-0338


  12 in total

Review 1.  Risk-adapted robotic stereotactic body radiation therapy for inoperable early-stage non-small-cell lung cancer.

Authors:  Susanne Temming; Martin Kocher; Erich Stoelben; Lars Hagmeyer; De-Hua Chang; Konrad Frank; Khosro Hekmat; Juergen Wolf; Wolfgang W Baus; Robert Semrau; Christian Baues; S Marnitz
Journal:  Strahlenther Onkol       Date:  2017-08-15       Impact factor: 3.621

2.  High-dose stereotactic body radiotherapy using CyberKnife® for stage I peripheral lung cancer: a single-center retrospective study.

Authors:  Yasuhiro Ryuno; Takanori Abe; Misaki Iino; Satoshi Saito; Tomomi Aoshika; Tomohiro Oota; Mitsunobu Igari; Ryuta Hirai; Yu Kumazaki; Kyoichi Kaira; Hiroshi Kagamu; Hironori Ishida; Shin-Ei Noda; Shingo Kato
Journal:  Radiat Oncol       Date:  2022-07-19       Impact factor: 4.309

Review 3.  SABR vs. Limited Resection for Non-small Cell Lung Cancer: Are We Closer to an Answer?

Authors:  Hanbo Chen; Alexander V Louie
Journal:  Curr Treat Options Oncol       Date:  2016-06

4.  A comparison of two modalities of stereotactic body radiation therapy for peripheral early-stage non-small cell lung cancer: results of a prospective French study.

Authors:  Line Claude; Magali Morelle; Marc-André Mahé; David Pasquier; Pierre Boisselier; Pierre Yves Bondiau; Emmanuel Touboul; Karine Peignaux-Casasnovas; Isabelle Martel-Lafay; Frederic Gassa; Lionel Perrier; Sophie Dussart; Veronique Beckendorf
Journal:  Br J Radiol       Date:  2020-09-24       Impact factor: 3.039

5.  Medically inoperable peripheral lung cancer treated with stereotactic body radiation therapy.

Authors:  K D Kelley; D L Benninghoff; J S Stein; J Z Li; R T Byrnes; L Potters; J P S Knisely; H D Zinkin
Journal:  Radiat Oncol       Date:  2015-05-28       Impact factor: 3.481

6.  Stereotactic body radiotherapy for centrally located early-stage non-small cell lung cancer or lung metastases from the RSSearch(®) patient registry.

Authors:  Joanne N Davis; Clinton Medbery; Sanjeev Sharma; John Pablo; Frank Kimsey; David Perry; Alexander Muacevic; Anand Mahadevan
Journal:  Radiat Oncol       Date:  2015-05-15       Impact factor: 3.481

7.  Clinical Outcomes of 130 Patients with Primary and Secondary Lung Tumors treated with Cyberknife Robotic Stereotactic Body Radiotherapy.

Authors:  Zsolt Levente Janvary; Nicolas Jansen; Veronique Baart; Magali Devillers; David Dechambre; Eric Lenaerts; Laurence Seidel; Nicole Barthelemy; Patrick Berkovic; Akos Gulyban; Ferenc Lakosi; Zsolt Horvath; Philippe A Coucke
Journal:  Radiol Oncol       Date:  2017-04-03       Impact factor: 2.991

8.  Prognosis of non-small-cell lung cancer in patients with idiopathic pulmonary fibrosis.

Authors:  SongYi Han; Yeon Joo Lee; Jong Sun Park; Young-Jae Cho; Ho Il Yoon; Jae-Ho Lee; Choon-Taek Lee; Jin-Haeng Chung; Kyung Won Lee; Sang Hoon Lee
Journal:  Sci Rep       Date:  2019-08-29       Impact factor: 4.379

Review 9.  Stereotactic body radiation therapy (SBRT) in the management of non-small-cell lung cancer: Clinical impact and patient perspectives.

Authors:  Elysia K Donovan; Anand Swaminath
Journal:  Lung Cancer (Auckl)       Date:  2018-03-16

10.  Fatal Radiation Pneumonitis: Literature Review and Case Series.

Authors:  Stephen Keffer; Christopher L Guy; Elisabeth Weiss
Journal:  Adv Radiat Oncol       Date:  2019-08-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.